{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:29:57Z","timestamp":1792740597078,"version":"4.5.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Maternal group B Streptococcus (GBS) infection is associated with substantial risk of preterm birth and infant mortality. Preventive approaches to protect infants from GBS infection are needed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this phase 2b randomized study, healthy nonpregnant 18- to 49-year-old females were randomized 1:1:1 to receive the investigational 6-valent GBS polysaccharide conjugate vaccine (GBS6) and concomitant tetanus, diphtheria, and acellular pertussis vaccine (Tdap) (GBS6 + Tdap), GBS6 and placebo (GBS6 + placebo), or Tdap and placebo (Tdap + placebo). Primary safety endpoints included reactogenicity events within 7 days and adverse events (AEs) through 1 month after vaccination. Primary immunogenicity objectives were to describe immune responses induced by GBS6 + Tdap versus Tdap + placebo and versus GBS6 + placebo for pertussis, tetanus, and diphtheria Tdap antigens and the 6 GBS6 antigens.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 304 participants received study vaccination. Most reactogenicity events were mild or moderate in severity and balanced across vaccine groups. Frequency of AEs was \u22648.1% across vaccine groups. One month after vaccination, the proportion of participants achieving antibody concentrations \u22650.1 IU\/mL for tetanus and diphtheria antigens was 100% in both the GBS6 + Tdap and Tdap + placebo groups. Immune responses to pertussis antigens were lower in the GBS6 + Tdap group compared to the Tdap + placebo group, with geometric mean ratios &amp;lt;0.6. No consistent effect on immune responses against each of the GBS6 serotypes after concomitant administration with Tdap was observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>GBS6 and Tdap administered concomitantly and alone were safe and well tolerated in healthy nonpregnant individuals. Similar immune responses were observed for Tdap when administered with GBS6 or when administered alone. These results will likely inform future studies in pregnant individuals.<\/jats:p>\n                  <jats:p>Clinical Trials Registration. NCT04766086.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiaf096","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T15:51:06Z","timestamp":1741103466000},"page":"e1065-e1074","source":"Crossref","is-referenced-by-count":16,"title":["A Phase 2b Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 6-Valent Group B <i>Streptococcus<\/i> Vaccine Administered Concomitantly With Tetanus, Diphtheria, and Acellular Pertussis Vaccine in Healthy Nonpregnant Female Individuals"],"prefix":"10.1093","volume":"231","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6907-9031","authenticated-orcid":false,"given":"William B","family":"Smith","sequence":"first","affiliation":[{"name":"Alliance for Multispecialty Research , Knoxville, Tennessee ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Seger","sequence":"additional","affiliation":[{"name":"Avacare , Fort Worth, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Chawana","sequence":"additional","affiliation":[{"name":"Vaccine Clinical Research and Development Pfizer Inc , Johannesburg, Gauteng ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Skogeby","sequence":"additional","affiliation":[{"name":"Vaccine Clinical Research and Development Pfizer Ltd , Marlow ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie C","family":"Silmon de Monerri","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer , Pearl River, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Feng","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer , Pearl River, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Gaylord","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer , Pearl River, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babalwa","family":"Jongihlati","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer , Pearl River, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Beeslaar","sequence":"additional","affiliation":[{"name":"Vaccine Clinical Research and Development Pfizer Ltd , Marlow ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M","family":"Skinner","sequence":"additional","affiliation":[{"name":"Vaccine Clinical Research and Development Pfizer Ltd , Marlow ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Bickham","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer , Pearl River, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annaliesa S","family":"Anderson","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer , Pearl River, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"2025071111113574400_jiaf096-B1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/AOG.0000000000003669","article-title":"Prevention of group B streptococcal early-onset disease in newborns: ACOG Committee opinion summary, number 797","volume":"135","year":"2020","journal-title":"Obstet Gynecol"},{"key":"2025071111113574400_jiaf096-B2","doi-asserted-by":"crossref","first-page":"ofad356","DOI":"10.1093\/ofid\/ofad356","article-title":"Stillbirths and neonatal deaths caused by group B Streptococcus in Africa and South Asia identified through child health and mortality prevention surveillance (CHAMPS)","volume":"10","author":"Mahtab","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2025071111113574400_jiaf096-B3","volume-title":"Streptococcus group B","author":"Hanna","year":"2024"},{"key":"2025071111113574400_jiaf096-B4","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.vaccine.2023.04.024","article-title":"Vaccine value profile for group B Streptococcus","volume":"41","author":"Trotter","year":"2023","journal-title":"Vaccine"},{"key":"2025071111113574400_jiaf096-B5","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1093\/cid\/cix664","article-title":"Estimates of the burden of group B streptococcal disease worldwide for pregnant women, stillbirths, and children","volume":"65","author":"Seale","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2025071111113574400_jiaf096-B6","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1093\/cid\/cix658","article-title":"Maternal colonization with group B Streptococcus and serotype distribution worldwide: systematic review and meta-analyses","volume":"65","author":"Russell","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2025071111113574400_jiaf096-B7","doi-asserted-by":"crossref","first-page":"e807","DOI":"10.1016\/S2214-109X(22)00093-6","article-title":"Group B Streptococcus infection during pregnancy and infancy: estimates of regional and global burden","volume":"10","author":"Gon\u00e7alves","year":"2022","journal-title":"Lancet Glob Health"},{"key":"2025071111113574400_jiaf096-B8","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/cei\/uxac066","article-title":"Group B Streptococcus (GBS) colonization is dynamic over time, whilst GBS capsular polysaccharide\u2013specific antibody remains stable","volume":"209","author":"Haeusler","year":"2022","journal-title":"Clin Exp Immunol"},{"key":"2025071111113574400_jiaf096-B9","doi-asserted-by":"crossref","first-page":"102748","DOI":"10.1016\/j.eclinm.2024.102748","article-title":"Intrapartum antibiotic prophylaxis to prevent group B streptococcal infections in newborn infants: a systematic review and meta-analysis comparing various strategies","volume":"74","author":"Panneflek","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2025071111113574400_jiaf096-B10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12884-023-05478-9","article-title":"The risk factors for group B Streptococcus colonization during pregnancy and influences of intrapartum antibiotic prophylaxis on maternal and neonatal outcomes","volume":"23","author":"Chen","year":"2023","journal-title":"BMC Pregnancy Childbirth"},{"key":"2025071111113574400_jiaf096-B11","first-page":"e280","article-title":"Prevention of early-onset neonatal group B streptococcal disease: green-top guideline No. 36","volume":"124","year":"2017","journal-title":"BJOG"},{"key":"2025071111113574400_jiaf096-B12","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/ijgo.15465","article-title":"Maternal GBS vaccination for preventing group B Streptococcus disease in newborns: a mini review of current evidence","volume":"166","author":"Kokori","year":"2024","journal-title":"Int J Gynaecol Obstet"},{"key":"2025071111113574400_jiaf096-B13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1473-3099(20)30478-3","article-title":"Safety and immunogenicity of a novel hexavalent group B Streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1\/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial","volume":"21","author":"Absalon","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2025071111113574400_jiaf096-B14","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00431-020-03659-8","article-title":"Neonatal and young infant sepsis by group B streptococci and Escherichia coli: a single-center retrospective analysis in Germany\u2014GBS screening implementation gaps and reduction in antibiotic resistance","volume":"179","author":"Doenhardt","year":"2020","journal-title":"Eur J Pediatr"},{"key":"2025071111113574400_jiaf096-B15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa2116045","article-title":"Potential for maternally administered vaccine for infant group B Streptococcus","volume":"389","author":"Madhi","year":"2023","journal-title":"N Engl J Med"},{"key":"2025071111113574400_jiaf096-B16","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1128\/JCM.02365-10","article-title":"International external quality assurance for laboratory identification and typing of Streptococcus agalactiae (group B streptococci)","volume":"49","author":"Afshar","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2025071111113574400_jiaf096-B17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/infdis\/jiz062","article-title":"A novel hexavalent capsular polysaccharide conjugate vaccine (GBS6) for the prevention of neonatal group B streptococcal infections by maternal immunization","volume":"220","author":"Buurman","year":"2019","journal-title":"J Infect Dis"},{"key":"2025071111113574400_jiaf096-B18","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1093\/cid\/cix656","article-title":"Infant group B streptococcal disease incidence and serotypes worldwide: systematic review and meta-analyses","volume":"65","author":"Madrid","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2025071111113574400_jiaf096-B19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41522-024-00497-6","article-title":"Bacterial capsules: occurrence, mechanism, and function","volume":"10","author":"Gao","year":"2024","journal-title":"NPJ Biofilms Microbiomes"},{"key":"2025071111113574400_jiaf096-B20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10719-023-10100-3","article-title":"Strengths and weaknesses of pneumococcal conjugate vaccines","volume":"40","author":"Micoli","year":"2023","journal-title":"Glycoconj J"},{"key":"2025071111113574400_jiaf096-B21","doi-asserted-by":"crossref","first-page":"1278346","DOI":"10.3389\/fimmu.2023.1278346","article-title":"Recent progress in pneumococcal protein vaccines","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"2025071111113574400_jiaf096-B22","author":"American College of Obstetricians and Gynecologists"},{"key":"2025071111113574400_jiaf096-B23","author":"Centers for Disease Control and Prevention"},{"key":"2025071111113574400_jiaf096-B24","doi-asserted-by":"crossref","first-page":"614","DOI":"10.15585\/mmwr.mm7328a1","article-title":"Progress toward achieving and sustaining maternal and neonatal tetanus elimination\u2014worldwide, 2000\u20132022","volume":"73","author":"Jones","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025071111113574400_jiaf096-B25","author":"Pan American Health Organization, World Health Organization"},{"key":"2025071111113574400_jiaf096-B26","author":"UK Health and Security Agency"},{"key":"2025071111113574400_jiaf096-B27","author":"Government of Canada"},{"key":"2025071111113574400_jiaf096-B28","author":"Australian Government Department of Health and Aged Care"},{"key":"2025071111113574400_jiaf096-B29","doi-asserted-by":"crossref","first-page":"2311480","DOI":"10.1080\/21645515.2024.2311480","article-title":"Development and validation of a 6-plex Luminex-based assay for measuring human serum antibodies to group B Streptococcus capsular polysaccharides","volume":"20","author":"Gaylord","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"2025071111113574400_jiaf096-B30","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1093\/infdis\/jiab505","article-title":"Safety and immunogenicity of a respiratory syncytial virus prefusion F vaccine when coadministered with a tetanus, diphtheria, and acellular pertussis vaccine","volume":"225","author":"Peterson","year":"2022","journal-title":"J Infect Dis"},{"key":"2025071111113574400_jiaf096-B31","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1016\/j.vaccine.2018.05.051","article-title":"MenACWY-TT is immunogenic when co-administered with Tdap and AS04-HPV16\/18 in girls and young women: results from a phase III randomized trial","volume":"36","author":"Rivera","year":"2018","journal-title":"Vaccine"},{"key":"2025071111113574400_jiaf096-B32","doi-asserted-by":"crossref","first-page":"e563","DOI":"10.1542\/peds.2014-4199","article-title":"Coadministration of a 9-valent human papillomavirus vaccine with meningococcal and Tdap vaccines","volume":"136","author":"Schilling","year":"2015","journal-title":"Pediatrics"},{"key":"2025071111113574400_jiaf096-B33","doi-asserted-by":"crossref","first-page":"5929","DOI":"10.1016\/j.vaccine.2016.10.020","article-title":"Effect of Tdap when administered before, with or after the 13-valent pneumococcal conjugate vaccine (coadministered with the quadrivalent meningococcal conjugate vaccine) in adults: a randomised controlled trial","volume":"34","author":"Tashani","year":"2016","journal-title":"Vaccine"},{"key":"2025071111113574400_jiaf096-B34","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1080\/14760584.2022.2137145","article-title":"The role of bactericidal and opsonic activity in immunity against Bordetella pertussis","volume":"21","author":"Blanc","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"2025071111113574400_jiaf096-B35","doi-asserted-by":"crossref","first-page":"858","DOI":"10.4161\/hv.9961","article-title":"Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adults","volume":"5","author":"Weston","year":"2009","journal-title":"Hum Vaccin"},{"key":"2025071111113574400_jiaf096-B36","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.vaccine.2010.11.057","article-title":"Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration","volume":"29","author":"Weston","year":"2011","journal-title":"Vaccine"},{"key":"2025071111113574400_jiaf096-B37","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1128\/CVI.00436-09","article-title":"Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults","volume":"17","author":"Gasparini","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"2025071111113574400_jiaf096-B38","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1016\/j.vaccine.2006.12.047","article-title":"Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults","volume":"25","author":"McNeil","year":"2007","journal-title":"Vaccine"},{"key":"2025071111113574400_jiaf096-B39","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1016\/j.vaccine.2019.08.001","article-title":"The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged \u226550 years: a randomized trial","volume":"37","author":"Strezova","year":"2019","journal-title":"Vaccine"},{"key":"2025071111113574400_jiaf096-B40","author":"World Health Organization and United Nations Children\u2019s Fund"},{"key":"2025071111113574400_jiaf096-B41","author":"World Health Organization (WHO)"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf096\/62178657\/jiaf096.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/6\/e1065\/62178657\/jiaf096.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/6\/e1065\/62178657\/jiaf096.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T15:11:45Z","timestamp":1752246705000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/231\/6\/e1065\/8043251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,2,26]]},"published-print":{"date-parts":[[2025,7,11]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf096","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6,15]]},"published":{"date-parts":[[2025,2,26]]}}}